◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral OPTIONAL-ADD MEDIUM

Bupropion

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Solid evidence for mood/motivation/anhedonia in target populations and clean stim-like profile without amphetamine harshness — but Dylan's daily subconcussive head-impact exposure (10+ hr/wk MMA + sparring) is the exact pattern FDA labeling and TBI literature flag for elevated seizure-threshold risk. Worth holding until baseline (modafinil + bromantane + selegiline) lands; revisit only if anhedonia/motivation persists, and only via XL formulation at 150 mg max with prescriber knowing the head-impact context.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    post-baseline. Reserve until V5 baseline (modafinil 100 mg + bromantane 50 mg + selegiline 1–2.5 mg + Adamax/Semax) is established for 6–8 weeks. Add ONLY if mood/motivation/anhedonia remains a deficit. 150 mg XL ceiling; full prescriber disclosure of MMA training; never IR formulation. If anxiety dominates the deficit pattern, skip in favor of agomelatine or other path. Medium confidence — mostly because the seizure-threshold gray zone is hard to fully resolve without prospective data.

  • 30-50, executive maintenance
    STRONG-CANDIDATE

    for energy + focus + atypical-depression-style fatigue. Best-tolerated antidepressant for cognition, no sexual side effects, mild weight loss, daily-safe profile. 150 mg XL → 300 mg XL ladder. Particularly good for the "I have everything I should want but I don't feel motivated" presentation common in this demographic.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    if motivation/apathy is part of the picture. Note slower clearance + more drug-interaction surface area in this age group; lower starting dose (150 mg XL) and cardiovascular check (BP, HR) before initiation.

  • Anxiety-prone
    SKIP-FOR-NOW

    NE-pushing mechanism + DA-pushing mechanism is the wrong direction for anxiety-dominant phenotypes. Try agomelatine, low-dose mirtazapine, or non-pharmacologic routes first. Bupropion is for *anhedonic / atypical / fatigue-dominant* presentations, not GAD/panic.

  • High athletic load, tested status
    NOT

    WADA-banned (irrelevant for Dylan but relevant for others). Cardiovascular load is real (mild HR/BP elevation) — monitor. For combat sports specifically, the seizure-during-competition risk is uniquely high — disclose to physician + accept the risk consciously or skip.

  • Sleep-disordered
    CAUTION

    Up to 45% insomnia rate at 300 mg. AM-only XL dosing solves this for most. Do not add if behavioral sleep is unfixed.

  • Recovery-focused (post-injury, post-illness)
    NEUTRAL

    Doesn't accelerate or impair recovery. Mood lift can support compliance with rehab. If post-TBI specifically: SSRIs first-line, bupropion XL only with careful neurologist sign-off.

  • Strength/anabolic-focused
    NEUTRAL

    to SLIGHTLY-NEGATIVE. Mild appetite suppression can work against bulking goals. Mild thermogenic effect. Not anabolic-axis suppressing. Useful for cut phases if motivation is the limiter.

  • Athletic with eating concerns / disordered eating history
    CONTRAINDICATED

    FDA label is explicit. Bupropion lowers seizure threshold and the eating-disorder-electrolyte combo dramatically amplifies seizure risk. No exceptions.

  • History of head injury / concussion (clinical TBI)
    AVOID

    unless extended-release only and explicitly cleared by neurology. SSRIs are first-line for post-TBI mood disorders.

▸ Subjective experience (deep)

Onset is gradual over 1–4 weeks, not acute like a stimulant — though some users notice energy/motivation shifts within 3–7 days due to NE effects appearing earlier than DA-mediated mood lift.

Characteristic profile (consensus from clinical reports + user forums):

  • Clean motivation lift — "I want to do things again," return of drive without artificial euphoria
  • Anhedonia relief — pleasure/interest in previously-flattened activities returns
  • Mild stimulant-like alertness, brighter mornings — but without the amphetamine harshness, jaw-clench, social-edge, or come-down
  • Subtle focus + executive function support, less ADHD-like distractibility
  • Reduced appetite (~early weeks especially), modest weight loss
  • Sometimes sexual function improves (opposite of SSRIs)
  • "Like coffee but cleaner" or "wake-up-from-fog" reports common

Anxiety profile (the catch):

  • ~7% of FDA-trial patients reported anxiety vs 5% placebo — small but real signal
  • First 1–2 weeks tend to be the worst; many users normalize by week 4
  • Higher doses (300 mg) more anxiety-flavored than 150 mg
  • For users with anxiety-dominant presentations, bupropion can backfire — its NE-pushing mechanism is the opposite of what those patients need
  • For users with anhedonic depression / atypical depression / fatigue-dominant ADHD, bupropion's NE+DA lift is the ideal profile

Insomnia: Up to ~45% incidence at 300 mg in clinical trials — highest of any second-gen antidepressant except desvenlafaxine. Almost entirely solvable by AM-only dosing; XL formulation makes this manageable for most.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal. Bupropion is one of the few "stim-flavored" agents where users genuinely don't escalate. Antidepressant tolerance is biologically distinct from amphetamine tolerance — the mechanism of action doesn't drive receptor downregulation in the same dopaminergic-axon-fatigue pattern.
  • Tachyphylaxis ("antidepressant poop-out") is real but uncommon — affects ~10–25% of long-term antidepressant users across drug classes; not bupropion-specific.
  • No recommended cycling. Steady-state daily use is the design.
  • Reset protocol if needed: Drug holiday of 4–6 weeks if poop-out emerges; consider switch to a different mechanism.
  • Discontinuation: Withdrawal symptoms are unusually mild for an antidepressant (because no serotonergic effect = no serotonin discontinuation syndrome). Some users get 1–2 weeks of irritability, headache, sleep changes. Tapering 150→0 over 1–2 weeks is conservative and adequate; 300→150→0 over 2–3 weeks for higher doses.
▸ Stacking deep dive

Synergistic with

  • modafinil: Mechanism complementarity — modafinil pushes orexin/histamine/glutamate wake systems with mild DA effect; bupropion adds stronger DA + NE reuptake inhibition. Plausibly synergistic for the "anhedonia + low-motivation" presentation. Cited "6 RCTs support combo" claim is misattributed in encyclopedia (see Accuracy Flags) — actual evidence is case reports + clinical practice, not 6 RCTs. The 6-RCT meta-analysis is for modafinil augmentation of antidepressants generally, mostly SSRIs/SNRIs. Combo is reasonable but evidence-grade is B/C, not A.
  • l-tyrosine: Substrate for NE+DA synthesis; bupropion is a reuptake inhibitor. Pairing precursor + reuptake blockade is mechanistically coherent for stress-load + cognitive performance. No formal RCT data but logically sound. Use 500–1000 mg AM if stacking.
  • bromantane: Mild DA-system supporter (D2/D3 sensitization, possible tyrosine hydroxylase modulation). Different mechanism than bupropion; theoretically additive without obvious conflict. Both are stim-adjacent without classical stimulant tolerance — V5 stack-compatible.
  • caffeine: Murine data shows caffeine potentiates bupropion's nootropic effect; clinically users report the combo as smoother than either alone. No seizure-risk red flag at moderate caffeine intake.
  • NAC, citicoline, magnesium, fish oil, PS (V4 core): All stack-safe — no PK or PD conflicts.

Avoid stacking with

  • selegiline at MAO-B-non-selective doses (≥10–12 mg/day oral, Emsam patches at 9 mg+): Risk of hypertensive crisis from combined DA/NE elevation. Low-dose selegiline (1–2.5 mg/day, MAO-B-selective) is generally tolerable but the combo deserves prescriber oversight. Encyclopedia note: "Avoid with selegiline at higher tiers" is correct.
  • MAOIs (phenelzine, tranylcypromine, isocarboxazid): Absolute contraindication. Hypertensive crisis risk. 14-day washout in either direction.
  • Tramadol, codeine, methadone: Bupropion is a CYP2D6 inhibitor — these opioids require CYP2D6 to convert to active forms. Tramadol independently lowers seizure threshold + bupropion does too = ~4× seizure risk in combo. Avoid.
  • Other seizure-threshold-lowering meds: Antipsychotics (especially clozapine), systemic corticosteroids, quinolone antibiotics (ciprofloxacin etc.), antimalarials (mefloquine), theophylline. Co-administration requires explicit risk acceptance.
  • Stimulants (Adderall, Vyvanse, methamphetamine): Both push DA/NE — additive cardiovascular load + theoretical mania/psychosis risk. Bupropion + amphetamine isn't absolute contraindication but isn't synergistic either.
  • Cocaine/recreational stimulants: Case reports of bupropion-induced psychosis in former cocaine users (sensitized DA system). Irrelevant for Dylan (no recreational drug use) but worth noting.
  • St. John's Wort: CYP enzyme induction — unpredictable bupropion levels.

Neutral / safe co-administration

  • All V4 stack components: DHA, magnesium L-threonate, citicoline, NAC, phosphatidylserine, magnesium glycinate, curcumin phytosome, rhodiola, L-theanine, L-tryptophan (replacing glycine), D3+K2, beta-alanine, vitamin C
  • Creatine (no interaction)
  • Modafinil 100 mg AM (per stacking-synergy section above)
  • Bromantane 50 mg AM
  • Adamax / Semax (intranasal peptides — no PK conflict)
  • ALCAR 500 mg AM
  • BPC-157 / TB-500 / GHK-Cu (peptide healing stack)
  • Propranolol PRN (stack-safe; some users find low-dose propranolol useful for bupropion's mild adrenergic edge)
  • Apigenin (CYP3A4 inhibition is mild; bupropion is CYP2B6-metabolized — no clinically meaningful interaction)
▸ Drug interactions deep dive

Bupropion (and especially hydroxybupropion) is a moderate-to-strong CYP2D6 inhibitor. This is the most clinically important interaction axis.

Drugs whose levels INCREASE with bupropion (CYP2D6 substrates):

  • SSRIs: Fluoxetine, paroxetine, fluvoxamine — additive serotonergic risk; venlafaxine concentrations can rise significantly
  • Tricyclics: Amitriptyline, nortriptyline, imipramine, desipramine
  • Antipsychotics: Risperidone, haloperidol, aripiprazole, thioridazine — QT-prolongation risk
  • Beta-blockers: Metoprolol (substantial), carvedilol — bradycardia/hypotension risk
  • Antiarrhythmics: Flecainide, propafenone — proarrhythmia risk
  • Atomoxetine: Doubles or triples atomoxetine exposure
  • Tamoxifen: Reduced activation (bupropion blocks the CYP2D6 step that converts tamoxifen to its active form endoxifen) — relevant if female partner on hormone-positive breast cancer therapy

Drugs whose effect DECREASES with bupropion:

  • Codeine, tramadol, hydrocodone: All require CYP2D6 to convert to morphine/active opioid. Bupropion blocks this — analgesia is reduced. (Tramadol has the additional seizure-threshold issue noted above.)
  • Tamoxifen: As above

Bupropion levels are affected by:

  • CYP2B6 inducers (rifampin, ritonavir, efavirenz, phenobarbital, phenytoin): reduce bupropion exposure
  • CYP2B6 inhibitors (ticlopidine, clopidogrel): increase bupropion exposure
  • Bupropion itself can self-induce its metabolism modestly over weeks

Absolute contraindications:

  • MAOIs (any) — 14-day washout both directions
  • Active seizure disorder
  • Anorexia nervosa / bulimia (current or remitted)
  • Abrupt alcohol or sedative-hypnotic withdrawal
  • Concurrent linezolid or methylene blue (have MAOI activity)

Hormonal contraceptives: No clinically significant interaction (irrelevant for Dylan).

▸ Pharmacogenomics

CYP2B6 (primary metabolic enzyme — meaningful for response):

  • CYP2B6*6 allele (~16–25% frequency in European ancestry, higher in African): reduced metabolism → lower hydroxybupropion exposure, lower active-metabolite levels. Carriers may have diminished response at standard doses.
  • CYP2B6 ultra-rapid metabolizers: higher hydroxybupropion levels, possibly more side effects, possibly more seizure risk (theoretical).
  • No formal dose-adjustment guidelines yet (CPIC has not issued a bupropion guideline as of 2026).

CYP2D6 (downstream interaction enzyme):

  • CYP2D6 poor metabolizers (~7–10% of European ancestry): bupropion's CYP2D6 inhibition is essentially "ceiling-effect" already, so adding bupropion to an SSRI is even more impactful for these patients.
  • Bupropion can functionally convert CYP2D6 extensive metabolizers to poor metabolizers during use (phenotype switch), affecting any concurrent CYP2D6 substrate.

CYP2C19 (minor role): rapid metabolizers (*17 carriers) may have subtherapeutic bupropion concentrations; case report exists.

For Dylan (post-23andMe, ~June 2026):

  • Pull CYP2B6*6 status — if heterozygous or homozygous variant, expect reduced response and consider that 150 mg may be subtherapeutic functionally.
  • Pull CYP2D6 status — if poor metabolizer, all CYP2D6 drug interactions are amplified. Most relevant if any future opioid/antiarrhythmic use.
  • Nordic/British ancestry: *6 frequency ~25%, *4/*5 PM CYP2D6 ~7–10% — Dylan has moderate prior probability for either.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
US Rx generic — primary care Pharmacy + GoodRx $7–30/mo (XL 150–300 mg, 30 ct) High Standard route. Tell prescriber about MMA training.
US telehealth psychiatry Cerebral / Brightside / Done / Hers $49–99/mo (incl. visit) High Easy "low motivation / atypical depression / ADHD adjunct" presentation. Disclose MMA — providers who shrug it off are not the ones you want.
GoodRx Gold Pharmacy $5–15/mo (XL 300 mg) High Subscription savings if chronic
Brand Wellbutrin XL Pharmacy $500+/mo High No reason to use brand — generic XL is bioequivalent
Indian pharmacy (not recommended) n/a n/a Bupropion is cheap enough domestically that gray-market is pointless

Bottom line: this is the cheapest reasonable Rx in the entire V5 plan. Generic bupropion XL is a $5–30/month commodity.

▸ Biomarkers to track (deep)

  • Baseline (before starting):

    • Resting HR, BP (ideally averaged across 3 days)
    • Hepatic panel (ALT, AST) — baseline; bupropion is hepatically metabolized
    • PHQ-9 + GAD-7 scores for tracking response/side effects
    • Sleep quality baseline (subjective + Whoop/Oura if available)
    • Weight + appetite baseline
    • Once-23andMe-back: CYP2B6 + CYP2D6 phenotype

  • During use (especially first 8 weeks):

    • HR + BP weekly first month, then monthly — flag if BP rises >10 mmHg systolic
    • PHQ-9 / GAD-7 every 2 weeks first 2 months
    • Sleep quality (insomnia signal)
    • Anxiety self-rating
    • Any neurological prodromal symptoms — myoclonus, focal twitches, déjà vu episodes, brief unexplained zoning out, aura sensations → STOP IMMEDIATELY and contact prescriber
    • Weight monthly
    • LFTs at 6 weeks if any GI/abdominal symptoms

  • Post-cycle (if discontinuing):

    • Mood stability for 4 weeks
    • Re-baseline HR/BP after 2–4 weeks
    • Watch for rebound fatigue/anhedonia (separates "drug was working" from "I'm just naturally back to baseline")
▸ Controversies / open debates Live debate

  • Cognitive enhancement in healthy people: The single best healthy-volunteer trial (Siepmann, n=12, 300 mg) showed null cognitive effects with subtle EEG psychostimulant signature. Anecdotal Reddit/forum reports diverge sharply — they describe motivation/drive lift. Probable resolution: bupropion improves self-reported motivation/anhedonia but does NOT improve objective cognitive performance in healthy people. This is consistent with the "amphetamines and modafinil don't enhance healthy cognition either, when measured rigorously" pattern.

  • SSRI augmentation efficacy: Despite the popularity of "Welloft" and similar combos, the actual RCT evidence for bupropion-SSRI augmentation in treatment-resistant depression is mediocre to negative. STAR*D + replications failed to show clear benefit over SSRI switching. Clinical practice continues anyway because side-effect-mitigation (sexual function, fatigue) is a legitimate non-efficacy reason.

  • The "head trauma" contraindication: No published threshold defining what counts. Practical clinical interpretation varies wildly — some prescribers refuse for any concussion history, others ignore subconcussive/mild TBI. The literature offers minimal guidance for athletes.

  • Bupropion in adolescents/young adults (Dylan, 20): FDA black-box for suicidal ideation in <25yo applies to all antidepressants; the bupropion-specific signal isn't worse than SSRIs. Brain development concerns at 20 are theoretical — no data showing bupropion causes lasting neurological changes; mechanism (NDRI without amphetamine-class axon damage) is plausibly safer than amphetamines for this age group. Net: brain-development concern is lower than for amphetamines but non-zero.

  • The encyclopedia's "6 RCTs support modafinil + bupropion combo for depression/fatigue" claim: Incorrect attribution. The 6-RCT meta-analysis is for modafinil augmentation of antidepressants generally (mostly SSRIs/SNRIs in those trials, not bupropion). The modafinil + bupropion specific combination has only case reports + open-label experience, not RCTs. The combination is reasonable but evidence-grade is B/C, not A. (See Accuracy Flags.)

  • Bupropion as nootropic vs. antidepressant: Strong subjective reports in non-depressed users; objective cognitive testing in healthy people is null. Likely a "feels-better-than-it-tests" agent — which is fine for many real-world goals but means rigorous cognitive enhancement isn't the right framing.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD post-baseline (medium confidence). Hold until V5 baseline is established. Add only if mood/motivation/anhedonia remains a deficit at week 6–8 of V5. 150 mg XL ceiling, full prescriber disclosure of MMA training, never IR formulation. Reassess if Dylan's CYP2B6/CYP2D6 genotype reveals reduced metabolism (lower hydroxybupropion = possibly subtherapeutic at 150 mg) or any concussion event occurs.
▸ Open questions / gaps Open

  1. Subconcussive impact + seizure threshold: No prospective data exists on bupropion seizure risk specifically in athletes with chronic subconcussive exposure. The FDA label is conservative; published TBI literature focuses on diagnosed concussions/moderate-severe TBI. Dylan's risk profile is in a literature gap — likely small but unquantified.

  2. CYP2B6*6 frequency in Dylan's ancestry: ~25% in Northern European populations. If positive, hydroxybupropion exposure may be insufficient at 150 mg → either go to 300 mg (raises seizure question) or switch agents. 23andMe will resolve this by ~June 2026.

  3. Optimal sequencing with V5 stack: No data on bupropion + modafinil + bromantane + low-dose selegiline triple/quadruple combination. Theoretically coherent, no obvious red flags below selegiline 5 mg, but uncharted clinically.

  4. Anhedonia-specific dosing: Whether bupropion's anhedonia effect is dose-responsive in the 150–300 mg range, or whether 150 mg XL is sufficient for non-depressed users seeking motivation lift specifically. Anecdotally many users report 150 mg XL is enough; no formal dose-finding data in this use case.

  5. Long-term (5+ year) cognitive outcomes: No data on cumulative effects of NDRI use over decades. Theoretical concerns about chronic dopaminergic tone are minimal but unstudied.

▸ Sources (full, with our context)
Back to compact view